BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Jun 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Intelligence
6/8 — Comprehensive
PROLIA (denosumab) by Amgen is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2010.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
Started Feb 2026
358 enrolled
Type 2 DiabetesOsteoporosisFractures
Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia®
Started Oct 2025
0Osteoporosis
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
Started Jul 2025
12 enrolled
OsteoarthritisOsteoarthritis (OA) of the KneeOsteoporosis+2 more
A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia®
Started Jun 2025
278 enrolled
Postmenopausal Women With Osteoporosis at High Risk of Fracture
A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China
Started May 2025
100 enrolled
Glucocorticoid-induced Osteoporosis
Worked on PROLIA at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.